Stéphanie Henry

Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

Robert L. Coleman, Domenica Lorusso, Christine Gennigens et al. · The Lancet Oncology · 2021 · 394 citations

Medicine, Oncology, Pharmacotherapy +13

Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy

Dan P. Zandberg, Alain P. Algazi, Antonio Jimeno et al. · European Journal of Cancer · 2018 · 267 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Jean‐Pascal Machiels, Yungan Tao, Lisa Licitra et al. · The Lancet Oncology · 2024 · 210 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase II Study of Sunitinib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: GORTEC 2006-01

Jean‐Pascal Machiels, Stéphanie Henry, Sylvie Zanetta et al. · Journal of Clinical Oncology · 2009 · 170 citations · Full text

Medicine, Oncology, Pharmacology +17

Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study

J. Guigay, Jérôme Fayette, Anne-Françoise Dillies et al. · Annals of Oncology · 2015 · 146 citations · Full text

Medicine, Oncology, Chemotherapy +10